The patient with systemic lupus erythematosus (SLE) is at risk of osteoporosis through several factors: the inflammatory disease itself, disease-related co-morbidity, and its treatment. Bone loss is apparent early in the disease and this may be confounded primarily by treatment with corticosteroids. Patients should be assessed for additional risk factors for osteoporosis and general lifestyle measures adopted. Bone mineral density measurement should be considered in SLE patients at high risk of osteoporosis, particularly those starting corticosteroids and in postmenopausal women. Calcium and vitamin D supplementation provide general prophylaxis and are a suitable first-line option. Hormone replacement should be used in hypogondal subjects unless contra-indicated. In subjects at high fracture risk, particularly in postmenopausal women, bisphosphonate therapy should be considered as these agents have been shown to significantly reduce vertebral fracture risk. These measures should reduce the burden of osteoporosis and fracture in patients with lupus.
Bouillon R , Burkhardt P , Christiansen C et al. Consensus development conference: prophylaxis and treatment of osteoporosis . Osteoporos Int1991; 1: 114-117 .
2.
World Health Organization . Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. Technical Report Series 843. WHO: Geneva , 1994.
3.
Dhillon VB , Davies MC , Hall ML et al. Assessment of the effect of oral corticosteroids on bone mineral density in systemic lupus erythematosus: a preliminary study with dual energy X-ray absorptiometry . Ann Rheum Dis1990; 49: 624-626 .
4.
Kalla AA , van Wyk Kotze TJ , Meyers OL . Metacarpal bone mass in systemic lupus erythematosus . Clin Rheumatol1992; 11: 475-482 .
5.
Formiga F , Moga I , Nolla JM et al. Loss of bone mineral density in premenopausal women with systemic lupus erythematosus . Ann Rheum Dis1995; 54: 274-276 .
6.
Kalla AA , Fataar AB , Jessop SJ , Bewerunge L . Loss of trabecular bone mineral density in systemic lupus erythematosus . Arthrit Rheum1993; 36: 1726-1734 .
7.
Kipen Y , Buchbinder R , Forbes A et al. Prevalence of reduced bone mineral density in systemic lupus erythematosus and the role of steroids . J Rheumatol1997; 24: 1922-1929 .
8.
Sels F , Dequeker J , Verwilghen J , Mbuyi-Muamba JM . SLE and osteoporosis: dependence and/or independence on glucocorticoids . Lupus1996; 5: 89-92 .
9.
Pons F , Peris P , Guanabens N et al. The effect of systemic lupus erythematosus and long term steroid therapy on bone mass in premenopausal women . Br J Rheumatol1995; 34: 742-746 .
10.
Teichman J , Lange U , Stracke, Federlin K . Bone metabolism and bone mineral density of systemic lupus erytematosus at the time of diagnosis . Rheumatol Int1999; 18: 137-140 .
11.
Redlich K , Ziegler S , Kiener HP et al. Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus . Ann Rheum Dis2000; 59: 308-310 .
12.
Swaak AJ , van der Brink HG , Smeenk RJ et al. Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 y, first evaluation . Rheumatology1999; 38: 953-958 .
13.
Cummings SR , Black DM , Nevitt MC et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group . Lancet1993; 341: 72-75 .
14.
Ramsey-Goldman R , Dunn JE , Cheng-Fang H et al. Frequency of fractures in women with systemic lupus erythematosus . Arthrit Rheum1999; 42: 882-890 .
15.
Cummings SR , Nevitt MC , Browner WS et al. Risk factors for hip fracture in white women . New Engl J Med1995; 332: 767-773 .
16.
Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthrit Rheum1982; 25: 1271-1277 .
17.
Sinigaglia L , Varenna M , Binelli L et al. Determinants of bone mass in systemic lupus erythematosus: a cross sectional study on pre-menopausal women . J Rheumatol1999; 26: 1280-1284 .
18.
Gilboe IM , Kvien TK , Haugeberg, Husby G . Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls . Ann Rheum Dis2000; 59: 110-115 .
19.
Jardinet D , Lefeebvre C , Depresseux G et al. Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine . Rheumatology2000; 39: 389-392 .
20.
Wong CK , Li EK , Ho CY , Lam CWK . Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus . Rheumatology2000; 39: 1078-1081 .
21.
Ralston SH . Analysis of gene expression in human bone biopsies by polymerase chain reaction: evidence for enhanced cytokine expression in postmenopausal osteoporosis . J Bone Miner Res1994; 9: 883-890 .
22.
Pacifici R . Postmenopausal osteoporosis: how the hormonal changes of menopause cause bone loss. In: Marcus R , Feldman D , Delsey J (eds). Osteoporosis. Academic Press: San Diego, CA , 1996, pp 727-743.
23.
Gough AK , Lilley J , Eyre S et al. Generalised bone loss in patients with early rheumatoid arthritis . Lancet1994; 344: 23-27 .
24.
Cooper C , Mitchell M , Wickham C . Rheumatoid arthritis, corticosteroid therapy and the risk of hip fracture . Ann Rheum Dis1995; 54: 49-52 .
25.
Star VL , Hochberg MC . Osteoporosis in patients with rheumatic diseases . Rheum Dis Clin N Am1994; 20: 561-576 .
26.
Kipen Y , Briganti EM , Strauss BJG , Littlejohn GO , Morand EF . Three year follow-up of body composition changes in pre-menopausal women with systemic lupus erythematosus . Rheumatology1999; 38: 59-65 .
27.
Van Staa TP , Leufkens HG , Abenhaim L , Zhang B , Cooper C . Use of oral corticosteroids and risk of fractures . J Bone Miner Res2000; 15: 993-1000 .
LoCascio V , Bonucci E , Imbimbo B et al. Bone loss in response to long-term glucocorticoid therapy . Bone Miner1990; 8: 39-51 .
30.
Dempster DW , Arlot MA , Meunier PJ . Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis . Calcif Tissue Int1983; 35: 410-417 .
31.
Canalis E . Mechanism of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis . J Clin Endocrinol Metab1996; 81: 3441-3447 .
32.
Hseuh AJ , Erickson GF . Glucocorticoid inhibition of FSH-induced estrogen production in cultured rat granulosa cells . Steroids1978; 32: 639-648 .
33.
Reid IR , Ibbertson HK , France JT et al. Plasma testosterone concentration in asthmatic men treated with glucocorticoids . Br Med J1985; 291: 574–574 .
34.
Crilly IG , Cawood M , Marshall DH et al. Hormonal status in normal, osteoporotic and corticosteroid-treated postmenopausal women . JR Soc Med1978; 71: 733-736 .
35.
Zonana-Nacach A , Barr SG , Magder LS , Petri M . Damage in systemic lupus erythematosus and its association with corticosteroids . Arthrit Rheum2000; 43: 1801-1808 .
36.
Star VL , Hochberg MC . Osteoporosis in patients with rheumatic diseases . Rheum Dis Clin1989; 20: 561-576 .
37.
Menon RK , Gill DS , Thomas M et al. Impaired carboxylation of osteocalcin in warfarin treated patients . J Clin Endocrinol Metab1987; 64: 59-61 .
FeldkampJ, Becker A , Witte OW , Scharff D , Scherbaum WA . Long-term anticonvulsant therapy leads to low bone mineral density—evidence for direct drug effects of phenytoin and carbamazepine on human osteoblastlike cells . Exp Clin Endocrinol Diabetes2000; 108: 37-43 .
40.
Eastell R , Reid DM , Compston J et al. A UK consensus group on management of glucocorticoid-induced osteoporosis: an update . J Intern Med1998; 244: 271-292 .
41.
American College of Rheumatology task force on osteoporosis guidelines . Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis . Arthrit Rheum1996; 39: 1791-1801 .
42.
Sambrook PN . Corticosteroid osteoporosis: practical implications of recent trials . J Bone Miner Res2000; 15: 1645-1649 .
43.
Amin S , LaValley MP , Simms RW , Felson DT . The role of vitamin D in corticosteroid-induced osteoporosis . Arthrit Rheum1999; 42: 1740-1751 .
44.
Lambrinoudaki I , Chan DT , Lau CS et al. Effect of calcitriol on bone mineral density in premenopausal women taking chronic steroid therapy. A randomised, double blind controlled study . J Rheumatol2000; 27: 1759-1765 .
45.
Kung AW , Chan TM , Lau CS , Wong RW , Yeung SS . Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomised cotrolled trial of calcitriol and hormone replacement therapy . Rheumatology1999; 38: 1239-1344 .
46.
Arden NK , Lloyd ME , Spector TD et al. The safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE) . Lupus1994; 3: 11-13 .
47.
Delmas PD , Bjarnason NH , Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women . New Engl J Med1997; 337: 1641-1647 .
48.
Ettinger B , Black DM , Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators . JAMA1999; 282: 637-645 .
49.
Van Vollenhaven RF . Dehydroepiandrosterone in systemic lupus erythematosus . Rheum Dis Clin N Am2000; 26: 349-362 .
50.
Sambrook P , Birmingham J , Kempler S et al. Prevention of corticosteroid osteoporosis-a comparison of calcium, calcitriol and calcitonin . New Engl J Med1993; 328: 1747-1752 .
51.
Montemurro L , Schiraldi G , Fraioli P et al. Prevention of corticosteroid induced osteoporosis with salmon calcitonin in sarcoid patients . Calcif Tissue Int1991; 49: 71-76 .
52.
Healey JH , Paget SA , Williams-Russo P et al. A randomised controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica . Calcif Tissue Int1996; 58: 73-80 .
53.
Luengo M , Pons F , Martinez deOsaba MJ , Picado C . Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study . Thorax1994; 49: 1099-1102 .
54.
Adachi JD , Bensen WG , Brown J et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis . New Engl J Med1997; 337: 382-387 .
55.
Saag K , Emkey R , Cividino A et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis . New Engl J Med1998; 339: 292-299 .
56.
Cohen S , Levy RM , Keller M et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study . Arthrit Rheum1999; 42: 2309-2318 .
57.
Reid DM , Hughes RA , Laan RF et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study . J Bone Miner Res2000; 15: 1006-1013 .
58.
Lane NE , Sanchez S , Modin GW et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis . J Clin Invest1998; 102: 1627-1633 .
